J.P. Morgan expects a guidance lift for Novo Nordisk stock

Published on 10/23/2026 at 09:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

J.P. Morgan expects higher sales and profit guidance on November 4. Novo Nordisk stock costs EUR 35.28 on October 23, 2026 versus EUR 35.30 Xetra close.

November results set the test

On October 22, 2026, J.P. Morgan expected higher sales and operating profit guidance.
Novo Nordisk had repurchased DKK 10.56 billion by October 9, 2026.
Novo Nordisk stock trades at EUR 35.28 at 9:38 a.m. CEST at Lang & Schwarz on October 23, 2026, minus 0.06 percent below the Xetra close of October 22, 2026.

Bauhaus-Poster mit stilisierten Hormon-Molekülen in Blau, Weiß und Grau — Novo Nordisk A/S (DK0062498333): stilisierte Hormon-Moleküle als Bauhaus-Poster in Blau, Weiß und Grau auf Schwarz, Illustration mit AI erstellt.

Novo Nordisk (ISIN DK0062498333) was trading at EUR 35.28 at Lang & Schwarz on October 23, 2026 at 9:38 a.m. CEST. Medwatch reported on October 22, 2026 that J.P. Morgan expects Novo Nordisk to lift its sales and operating profit outlook with the third-quarter report.

Guidance is the November test

The expectation matters because Novo Nordisk is scheduled to publish third-quarter results on November 4, 2026. J.P. Morgan links the potential guidance change to demand for the Wegovy pill, while the company enters the report with full-year adjusted sales growth guidance of minus 6 percent to 0 percent, as cited in the current market coverage.

The valuation already reflects a weaker year. Novo Nordisk stock stood at EUR 35.28 on October 23, 2026, which was 35.71 percent below the EUR 54.88 52-week high and 17.21 percent above the EUR 30.10 low.

Three dates frame the setup

On October 9, 2026, Novo Nordisk had repurchased 37.85 million B shares for DKK 10.56 billion, according to investing.de. On October 19, 2026, the same report identified November 4 as the date for the third-quarter figures. On October 22, 2026, Medwatch carried J.P. Morgan's expectation of higher sales and operating profit guidance.

What does the buyback mean?

The repurchase provides a quantified capital-return counterweight to the operating questions. The program allows purchases of up to DKK 15 billion, and the 37.85 million shares already bought represented 1.2 percent of the share capital by October 9, 2026, according to investing.de. That scale gives the upcoming report two separate reference points: operating guidance and capital allocation.

November 4 is the next date

The next substantiated event is the third-quarter results release on November 4, 2026. For investors, the key comparison will be whether the reported sales and operating profit outlook moves beyond the current adjusted sales growth range of minus 6 percent to 0 percent.

Stock stays below its yearly high

Novo Nordisk had a market capitalization of EUR 119.0 billion on October 23, 2026, while its EUR 35.28 price remained 35.71 percent below the EUR 54.88 52-week high. The stock was trading at EUR 35.28 at Lang & Schwarz on October 23, 2026 at 9:38 a.m. CEST, minus 0.06 percent versus the Xetra close of October 22, 2026 (EUR 35.30). The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.